Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Lianyu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3731-8592; OpenAlex author ID A5018913195. Sources: OpenAlex.

Their work

Papers
36 (first author 3, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 5 papers · 2019: 5 papers · 2020: 5 papers · 2021: 4 papers · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 3 papers

Papers 36

  1. Strand-specific functions of miR-301a-3p and -5p drive opposing roles in pancreatic cancer via ferroptosis and pyroptosis. Last author DOI 10.1007/s10565-025-10096-6↗
  2. Hyaluronic acid and its role in pancreatic cancer: Mechanisms of tumor progression, drug resistance, and therapeutic targeting. Last author DOI 10.1016/j.phrs.2025.107958↗
  3. Lactate-associated gene MCU promotes the proliferation, migration, and invasion of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-025-14319-1↗
  4. Novel silicene-mesoporous silica nanoparticles conjugated gemcitabine induced cellular apoptosis via upregulating NF-κB p65 nuclear translocation suppresses pa… Last author DOI 10.1088/1361-6528/ad312a↗
  5. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. Last author DOI 10.1177/2515690x241291381↗
  6. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Co-author DOI 10.1186/s12863-021-01019-5↗
  7. Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ijms231810231↗
  8. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Co-author DOI 10.1002/ctm2.467↗
  9. A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-0256↗
  10. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling. Co-author DOI 10.1186/s12885-021-08158-z↗
  11. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Co-author DOI 10.21037/atm-20-1013↗
  12. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s12885-020-07023-9↗
  13. Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling. Last author DOI 10.1186/s13578-020-00457-5↗
  14. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Last author DOI 10.18632/aging.102638↗
  15. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis Co-author DOI 10.21203/rs.2.24244/v1↗
  16. Paeonol Inhibits Pancreatic Cancer Cell Migration and Invasion Through the Inhibition of TGF-β1/Smad Signaling and Epithelial-Mesenchymal-Transition. Co-author DOI 10.2147/cmar.s224416↗
  17. Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines. Co-author DOI 10.1016/j.bbrc.2019.02.092↗
  18. Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2019/1356264↗
  19. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12967-019-1782-x↗
  20. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Co-author DOI 10.1186/s13046-019-1055-9↗
  21. Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology … Co-author DOI 10.12659/msm.917106↗
  22. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2018.04.137↗
  23. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Co-author DOI 10.1155/2018/7343090↗
  24. Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Co-author DOI 10.2147/cmar.s167103↗
  25. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Co-author DOI 10.3390/ijms19061768↗
  26. Knockdown of FUT3 disrupts the proliferation, migration, tumorigenesis and TGF-β induced EMT in pancreatic cancer cells. First author DOI 10.3892/ol.2018.8738↗
  27. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Co-author PMID 28123853↗
  28. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  29. Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. Co-author PMID 27822411↗
  30. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-3097-8↗
  31. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Co-author DOI 10.1038/srep05911↗
  32. MicroRNA expression in salivary supernatant of patients with pancreatic cancer and its relationship with ZHENG. First author DOI 10.1155/2014/756347↗
  33. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0096177↗
  34. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Co-author DOI 10.1053/j.gastro.2013.07.048↗
  35. High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis. First author DOI 10.3109/02656736.2012.713541↗
  36. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Co-author DOI 10.3109/02656736.2010.525588↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen Chen · 25 shared papers, 2011–2022 · strength 2.39
  2. Chien‐shan Cheng · 14 shared papers, 2018–2025 · strength 2.03
  3. Zhiqiang Meng · 18 shared papers, 2011–2021 · strength 1.38
  4. Jiangang Zhao · 4 shared papers, 2020–2025 · strength 1.01
  5. Shu Dong Ma · 6 shared papers, 2016–2024 · strength 0.98
  6. Wenxun Cai · 3 shared papers, 2025 · strength 0.88
  7. Yuhang Chen · 3 shared papers, 2024–2025 · strength 0.83
  8. Huifeng Gao · 6 shared papers, 2018–2022 · strength 0.79
  9. Chao Qu · 8 shared papers, 2014–2021 · strength 0.67
  10. Hao Chen · 7 shared papers, 2014–2022 · strength 0.63
  11. Peng Wang · 10 shared papers, 2011–2021 · strength 0.62
  12. Peiwen Yang · 2 shared papers, 2024 · strength 0.54
  13. Yongqiang Hua · 5 shared papers, 2016–2021 · strength 0.49
  14. Panling Xu · 2 shared papers, 2022–2024 · strength 0.42
  15. Hao Chen · 4 shared papers, 2018–2020 · strength 0.40
  16. Chenyue Zhang · 4 shared papers, 2016–2021 · strength 0.40
  17. Ke Zhang · 3 shared papers, 2019–2022 · strength 0.38
  18. Yawen Geng · 3 shared papers, 2020–2021 · strength 0.37
  19. Luming Liu · 5 shared papers, 2013–2019 · strength 0.35
  20. Yujie Li · 2 shared papers, 2022 · strength 0.35
  21. Zhouyu Ning · 4 shared papers, 2016–2021 · strength 0.33
  22. Weidong Shi · 3 shared papers, 2016–2021 · strength 0.27
  23. Xinghe Liao · 1 shared paper, 2025 · strength 0.27
  24. Fenglin Zhang · 1 shared paper, 2025 · strength 0.27
  25. Juying Jiao · 1 shared paper, 2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.